Search results
Showing 1291 to 1305 of 1433 results for primary care
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]
Discontinued Reference number: GID-TA10324
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued Reference number: GID-TA10315
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued Reference number: GID-TA10295
Discontinued Reference number: GID-TA10628
Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults.
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.
Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)
This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs
Discontinued Reference number: GID-TA10591
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
Discontinued Reference number: GID-TA10221
November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued Reference number: GID-TA10418
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
Discontinued Reference number: GID-TA10158
Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]
Discontinued Reference number: GID-TA10228
In development Reference number: GID-TA11269 Expected publication date: TBC